Two Electroacupuncture Waveforms for Different Severity Groups of Bell Palsy

Sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06063954
Collaborator
The First Affiliated Hospital of Zhejiang Chinese Medical University (Other), Zhejiang University (Other)
120
1
2
12
10

Study Details

Study Description

Brief Summary

Bell palsy (BP) is the most common cause of acute facial palsy, which leads to functional and esthetic disturbances for patients and results in a lowered quality of life. Electroacupuncture (EA) received attention as an alternative and complementary treatment method. The low-frequency continuous wave EA and the intermittent wave EA have been used in the management of BP. The aim of this study is to compare the efficacy and safety of these two electroacupuncture waveforms for different severity groups of BP.

Condition or Disease Intervention/Treatment Phase
  • Other: electroacupuncture
N/A

Detailed Description

We will recruit 60 patients with BP whose ENoG test indicate a mild to moderate facial nerve damage, as indicated by the ratio of amplitude of the compound muscle action potential (CMAP) of the affected side comparing to normal side is 20% or higher. And we will recruit 60 patients with BP whose ENoG test indicate a severe damage, as indicated by the ratio of amplitude of the CMAP of the affected side comparing to normal side is less than 20%. Both the two types of patients will be randomly divided into either the low-frequency continuous wave group, or the intermittent wave group, and receive 4 weeks treatment. The primary outcomes is change from baseline score of the Facial Nerve Grading System 2.0. The secondary outcomes are change from baseline score of the Sunnybrook grading scale, and change from baseline value of the amplitude of the CMAP of the affected side in the ENoG test.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized Trial Comparing Two Electroacupuncture Waveforms for Different Severity Groups of Bell Palsy
Anticipated Study Start Date :
Sep 23, 2023
Anticipated Primary Completion Date :
Sep 23, 2024
Anticipated Study Completion Date :
Sep 23, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low-frequency continuous wave group

Low-frequency continuous wave EA In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.

Other: electroacupuncture
Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.

Experimental: Intermittent wave group

Intermittent wave EA In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz intermittent wave will be used for 20 min.

Other: electroacupuncture
Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline score of the Facial Nerve Grading System 2.0 [Baseline, the end of week 4]

    Evaluation of the facial nerve function using the Facial Nerve Grading System 2.0 (FNGS 2.0). In the FNGS 2.0, the minimal score is 4, which indicates normal function, and the maximal score is 24, which indicates the worst function.

Secondary Outcome Measures

  1. Change from Baseline score of the Sunnybrook grading scale. [Baseline, the end of week 4]

    Evaluation of the facial nerve function using the Sunnybrook grading scale. The Sunnybrook grading scale includes 3 subscales, which are the resting symmetry subscale, the symmetry of voluntary movement subscale, and the synkinesis subscale. Change from baseline score of each subscale and change from baseline of the composite score will be calculated.

  2. Change from Baseline value of the amplitude of the compound muscle action potential (CMAP) of the affected side in the ENoG test. [Baseline, the end of week 4]

    The compound motor action potential (CMAP) represents the summated action potentials of all stimulated motor endplates and potentially reflects muscle hypertrophy and increased muscle contractions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Diagnosed as BP by specialist.

  2. The score of FNGS 2.0 ≥ 15 at the day 21 since the onset of BP.

  3. 18 years ≤ age ≤ 65 years.

  4. Received prednisolone within 72 hours since initial symptoms of BP, the prednisolone dose used was 60 mg per day for 5 days and then reduced by 10 mg per day.

  5. Signed informed consent and volunteered to participate in this study.

Exclusion Criteria:
  1. Facial palsy caused by other diseases or injury.

  2. Ramsey-Hunt syndrome.

  3. Bilateral facial palsy.

  4. History of previous facial palsy.

  5. Manifesting facial spasm, facial synkinesis or contracture at day 21 since the onset of BP.

  6. History of surgery on face.

  7. Combined with uncontrolled diabetes mellitus, uncontrolled hypertension, serious heart, liver, kidney damage or cognitive impairment, aphasia, mental disorders.

  8. Installing pacemakers.

  9. Pregnant and lactating patients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Third Affiliated hospital of Zhejiang Chinese Medical University Hangzhou Zhejiang China 310053

Sponsors and Collaborators

  • The Third Affiliated hospital of Zhejiang Chinese Medical University
  • The First Affiliated Hospital of Zhejiang Chinese Medical University
  • Zhejiang University

Investigators

  • Principal Investigator: Jing Sun, MD, Ph.D, The Third Affiliated hospital of Zhejiang Chinese Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jing Sun, Deputy Chief physician of Traditional Chinese Medicine, The Third Affiliated hospital of Zhejiang Chinese Medical University
ClinicalTrials.gov Identifier:
NCT06063954
Other Study ID Numbers:
  • GZY-ZJ-KY-23071-01
First Posted:
Oct 3, 2023
Last Update Posted:
Oct 3, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jing Sun, Deputy Chief physician of Traditional Chinese Medicine, The Third Affiliated hospital of Zhejiang Chinese Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2023